Antares Pharma Stock News

The transmucosal route includes oral, nasal, vaginal, and urethral and presents a challenge in the field of novel drug delivery technology. The transmucosal membranes are relatively permeable, have a rich blood flow and hence allow the rapid uptake of a

Market Intelligence Data has released a new report on the global Powder-Based Needle Free Injector market. The document gives a complete evaluation of the market. It understands market development through in-depth insights, tracking historical results and analysing current scenarios and

Shares of Antares Pharma, Inc. (NASDAQ:ATRS) gapped down before the market opened on Monday . The stock had previously closed at $3.76, but opened at $3.63. Antares Pharma shares last traded at $3.62, with a volume of 409 shares. A number of research analysts recently weighed in on the company. HC Wainwright decreased their target []

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q3 2021 Results - Earnings Call Transcript

Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EWING, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its third quarter 2021 finan

Pharmacokinetic data results expected in 1Q 2022 Pharmacokinetic data results expected in 1Q 2022

EWING, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief E

These healthcare stocks have their warts, but the price is right for long-term investors.

Antares Pharma's (ATRS) CEO Robert Apple on Q2 2021 Results - Earnings Call Transcript

Increased Revenue 39% Year-Over-Year to $45.0 Million

EWING, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its second quarter 2021 fina

EWING, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (

Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.

Ad hoc announcement pursuant to Art. 53 LR